Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
Announced Positive Updated Data from Ongoing Investigator-Initiated Phase 1/2 FRAME Study Evaluating VS-6766 and Defactinib Combination in Patients with Low-Grade…